鼻内联合用药改善持续性非变应性鼻炎鼻塞症状的临床研究

郭丽敏; 孙希才; 杨娟梅; 刘娟; 王德辉

doi:10.13201/j.issn.1001-1781.2015.03.013

鼻内联合用药改善持续性非变应性鼻炎鼻塞症状的临床研究

- 复旦大学附属眼耳鼻喉科医院耳鼻咽喉科(上海, 200031)

详细信息

通讯作者: 王德辉,E-mail:wangdehuient@sina.com

中图分类号: R765.21

收稿日期: 2014-08-21

Clinical study of the combination therapy with intranasal antihistamine and nasal corticosteroids in the treatment of nasal obstruction of persistent non-allergic rhinitis

- Department of Otorhinolaryngology, Eye Ear Nose and Throat Hospital of Fudan University, Shanghai, 200031, China

More Information

Corresponding author: WANG Dehui, E-mail: wangdehuient@sina.com

Received Date: 21 August 2014

摘要

摘要: 目的:评估鼻内联合应用鼻用抗组胺药氮卓斯汀鼻喷剂(AZENS)和鼻用激素丙酸氟替卡松鼻喷剂(FPNS)改善持续性非变应性鼻炎(NAR)鼻塞症状的有效性。方法:162例持续性NAR患者随机分为联合治疗组(AZENS+FPNS)和鼻用激素组(FPNS),比较2组患者在治疗前、治疗2周及6周时鼻塞症状的评分,并对治疗方案(包括方便性、不良反应、费用、疗效)进行总的满意度评价。结果:2组患者的鼻塞症状在治疗前、治疗2周和6周的3次评分均呈现逐次下降趋势,差异均有统计学意义(P<0.01);在治疗2周和6周时,联合治疗组患者鼻塞症状的改善明显优于鼻用激素组,差异均有统计学意义(P<0.01)。联合治疗组患者对治疗方案总的满意度评价优于鼻用激素组(P<0.05)。结论:鼻内联合用药能更快速有效地改善持续性NAR的鼻塞症状,同时具有良好的安全性和耐受性。
- 持续性非变应性鼻炎 /
- 抗组按药物 /
- 鼻用激素 /
- 鼻塞
Abstract: Objective: To determine if greater efficacy could be achieved with the intranasal antihistamine azelastine and the intranasal corticosteroid fluticasone propionate used concurrently in the treatment of nasal obstruction of persistent non-allergic rhinitis. Method: A total of 162 persistent non-allergic rhinitis cases with moderate to severe nasal obstruction were randomized to treatment with the following: the combination therapy or nasal corticosteroids monotherapy. Efficacy was assessed by change from baseline in nasal obstruction score at week 2 and week 6 visits. The perceptions of global treatment satisfaction(convenience, side effects, cost and effectiveness) in both groups were analyzed.Result: In both groups, the nasal obstruction score assessment descended significantly at week 2 and week 6 visits versus at baseline (all P<0.01). At week 2 and week 6 visits, the nasal obstruction score in the combination therapy groups were significantly improved than that in nasal corticosteroids monotherapy groups (all P<0.01). The perceptions of global treatment satisfaction in the combination therapy groups were significantly better (P<0.05).Conclusion: Azelastine nasal spray and intranasal corticosteroid in combination may provide a substantial therapeutic benefit for patients with persistent non-allergic rhinitis, especially nasal obstruction.The combination therapy was well tolerated and safety.
- persistent non-allergic rhinitis /
- azelastine nasal spray /
- nasal corticosteroids /
- nasal obstruction

HTML全文

参考文献(15)

[1]	LIEBERMAN P, KALINER M A, WHEELER W J. Open-label evaluation of azelastine nasal spray in patients with seasonal allergic rhinitis and nonallergic vasomotor rhinitis[J]. Curr Med Res Opin, 2005, 21:611-618.
[2]	HORAK, ZIEGLMAYER U P. Azelastine nasal spray for the treatment of allergic and nonallergic rhinitis[J]. Expert Rev Clin Immunol, 2009, 5:659-669.
[3]	LIEBERMAN P. The role of antihistamines in the treatment of vasomotor rhinitis[J]. WAO Journal, 2009, 2:156-161.
[4]	KALINER M A. A novel and effective approach to treating rhinitis with nasal antihistamines[J]. Ann Allergy Asthma Immunol, 2007, 99:383-391.
[5]	MYGIND N,ANDERSSON M.Topical glucoeortieosteroids in rhinitis clinical aspects[J].Acta Otolaryngol, 2006,126:1022-1029.
[6]	SALIB R J, HARRIES P C, NAIR S B, et al. Mechanisms and mediators of nasal symptoms in non-allergic rhinitis[J]. Clin Exp Allergy, 2008, 38:393-404.
[7]	许庚,顾之燕,韩德民,等. 关于限制滥用麻黄素类鼻腔减充血剂的建议[J]. 耳鼻咽喉-头颈外科,2003,10(3):186-188.
[8]	JACOBS R, LIEBERMAN P, KENT E, et al. Weather/temperaturesensitive-sensitive vasomotor rhinitis may be refractory to intranasal corticasteroid treatment[J].Allergy Asthma Proc,2009,30:120-127.
[9]	KALPAKLIOGLU A F, KAVUT A B. Comparison of azelastine versus triamcinolone nasal spray in allergic and nonallergic rhinitis[J]. Am J Rhinol Allergy, 2010, 24:29-33.
[10]	RATNER P H,HAMPEL F,BAVEL J V,et al. Combination therapy with azelastine hydrochloride nasal spray and fluticasone propionate nasal spray in the treatment of patients with seasonal allergic rhinitis[J]. Ann Allergy Asthma Immunol, 2008,100:74-81.
[11]	HAMPEL F C,RATNER P H,BAVEL J V,et al. Double-blind,placebo-controlled study of azelastine and fluticasone in a single nasal spray delivery device[J]. Ann Allergy Asthma Immunol, 2010,105:168-173.
[12]	DERENDORF H, MUNZEL U, PETZOLD U, et al. Bioavailability and disposition of azelastine and fluticasone propionate when delivered by MP29-02, a new aqueous nasal spray[J]. Br J Clin Pharmacol, 2012, 74:125-133.
[13]	CARR W, BERNSTEIN J, LIEBERMAN P, et al. A novel intranasal therapy of azelastine with fl uticasone for the treatment of allergic rhinitis[J]. J Allergy Clin Immunol, 2012, 129:1282-1289.
[14]	MELTZER E O, LAFORCE C, RATNER P, et al. MP29-02(a novel intranasal formulation of azelastine hydrochloride and fluticasone propionate) in the treatment of seasonal allergic rhinitis:a randomized, double-blind, place-controlled trial of efficacy and safety[J]. Allergy Asthma Proc, 2012, 33:324-332.
[15]	PRICE D, SHAH S, BHATIA S, et al. A new therapy (MP29-02) is effective for the long-term treatment of chronic rhinitis[J]. J Investig Allergol Clin Immunol, 2013, 23:495-503.